1-3 of 3
Leonard S Sender, MD
Close
Sort by
Journal Articles

High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials

Bijal Shah, MD, Van Huynh, MD, Leonard S. Sender, MD, Daniel W. Lee, III, MD, Januario E. Castro, MD, William G. Wierda, MD PhD, Andrew C. Dietz, MD MSCR, Gary J. Schiller, MD, Marie José Kersten, MD PhD, Rupert Handgretinger, MD PhD, Patrick Brown, MD, Lia Gore, MD, Nicola Gökbuget, MD, Joseph Rosenthal, MD MS, Marianna Sabatino, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Yizhou Jiang, PhD, Lynn Navale, MS, Shanna Stout, BS, Jeff S. Aycock, BA, Jeff Wiezorek, MD MS, Rajul Jain, MD, Alan S. Wayne, MD
Journal: Blood
Blood (2016) 128 (22): 2803.
https://doi.org/10.1182/blood.V128.22.2803.2803
Published: 2016
Journal Articles

Intensive Asparaginase Therapy in Young Adult Patients with Acute Lymphoblastic Leukemia: Treatment Patterns and Barriers to Asparaginase Use

Leonard S Sender, MD, Tina Doede, MS, MBA, Megan P. Hall, PhD, Celine Bernard, MBA
Journal: Blood
Blood (2015) 126 (23): 4913.
https://doi.org/10.1182/blood.V126.23.4913.4913
Published: 2015
Journal Articles

The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models

David A Fruman, PhD, Matthew Robert Janes, MPH, Sharmila Mallya, MS, Collin C Vu, MD, Marie P. Shieh, MD, Michael B. Lilly, MD, Leonard S Sender, MD, Michael B Martin, PhD, Pingda Ren, PhD, Yi Liu, PhD, Christian Rommel, PhD
Journal: Blood
Blood (2011) 118 (21): 2585.
https://doi.org/10.1182/blood.V118.21.2585.2585
Published: 2011